# A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

> **NCT04536688** · PHASE1 · COMPLETED · sponsor: **Regulus Therapeutics Inc.** · enrollment: 19 (actual)

## Conditions studied

- Polycystic Kidney Disease, Autosomal Dominant

## Interventions

- **DRUG:** RGLS4326

## Key facts

- **NCT ID:** NCT04536688
- **Lead sponsor:** Regulus Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-13
- **Primary completion:** 2021-11-12
- **Final completion:** 2021-11-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536688, "A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04536688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*